A Site Bio-Decontamination Strategy: From Equipment Qualification To Process Ownership

By Kate Marshall, Protak Scientific

Many pharmaceutical manufacturers rely on OEM-qualified bio-decontamination cycles as their foundation, but end users bear ultimate responsibility for demonstrating process robustness within their own facilities. Site-specific variables, such as seasonal humidity and temperature shifts, can affect cycle performance, and sites that have not evaluated these factors may pursue inefficient investigations when failures occur.

Progression toward a mature bio-decontamination strategy follows a model that moves from reactive to predictive, with site ownership shared across production, operations, technical, and quality teams. A formal strategy document should define how practices become more repeatable and robust, supported by meticulous equipment onboarding, acceptance testing, and documented qualification activities.

Enzyme indicators (EIs) leveraged alongside biological indicators (BIs) offer a practical tool for accelerating this progression, providing rapid results that can help teams identify risk areas, refine cycle parameters, and build a scientifically justified challenge location strategy. Applied routinely after validation, EIs also support drift detection and ongoing risk management. Ultimately, the more site-specific process evidence an organization accumulates beyond the OEM package, the more defensible its validation approach becomes for regulators and auditors.